Journal of Medicinal Chemistry
Article
t e r t - B u t y l N - [ ( 1 S ) - 5 - [ [ ( 2 S ) - 2 , 6 - B i s ( t e r t -
butoxycarbonylamino)hexanoyl]amino]-1-[[4-[2-(2,3,5,6-tetra-
fluoro-4-pyridyl)ethynyl]phenyl]carbamoyl]pentyl]carbamate
(11). To a solution of dipeptide 9 (300 mg, 0.522 mmol) in
THF:MeOH:H2O (3:1:1, 5 mL) at 0 °C, LiOH·H2O (65 mg, 2.40
mmol) was added and stirred at the room temperature for 3 h. The
reaction mixture was then acidified to pH 2 with 1N HCl. It was
extracted with ethyl acetate, washed with brine, dried (Na2SO4),
filtered, and concentrated in vacuo to get the crude acid.
40.4, 40.3, 32.3, 30.6, 28.2, 28.1, 26.4, 22.6. MS (ESI): m/z (%) 696
(100) [M + H]+. HRMS (ESI): calcd for C32H30F8N7O2 [M +H]+
696.23332, found 696.23180.
t e r t - B u t y l N - [ ( 5 S ) - 5 - [ [ ( 2 S ) - 2 , 6 - B i s ( t e r t -
butoxycarbonylamino)hexanoyl]amino]-6-oxo-6-[4-[2-(2,3,5,6-
tetrafluoro-4-pyridyl)ethynyl]anilino]hexyl]carbamate (13).
The peptide conjugate 13 was prepared by using the same procedure
as synthesis of compound 11 in 68% yield. 1H NMR (400 MHz,
CDCl3): δ 9.13 (bs, 1H), 7.81−7.73 (m, 2H), 7.54 (d, J = 8.7 Hz, 1H),
6.72 (bs, 1H), 5.80 (bs, 1H), 4.84−4.67 (m, 2H), 4.62−4.52 (m, 1H),
4.12−3.99 (m, 1H), 3.19−3.02 (m, 4H), 2.12−1.64 (m, 5H), 1.63−
1.33 (m, 34H). 13C NMR (100 MHz, CDCl3): δ 173.1, 170.4, 156.7,
156.6, 156.2, 144.6, 144.4 (dm, J = 245 Hz), 141.6 (dm, J = 270 Hz),
140.5, 133.2, 119.7, 117.6, 115.5, 107.1, 80.6, 79.3, 73.2, 55.5, 53.9,
40.0, 39.2, 31.4, 30.9, 29.5, 28.5, 28.4, 28.3, 22.8, 22.3. MS (ESI): m/z
(%) 845 (100) [M + Na]+. HRMS (ESI TOF): calcd for
C40H54F4N6O8Na [M + Na]+ 845.38369, found 845.38472.
The above prepared crude acid was dissolved in CH2Cl2 (10 mL)
and cooled to 0 °C. It was sequentially treated with HOBt (105 mg,
0.783 mmol) and DCC (161 mg, 0.783 mmol). After 15 min, amine 7
(205 mg, 0.783 mmol) was added to the reaction mixture and stirred
for 12 h, raising the temperature to rt. The reaction mixture was
extracted with ethyl acetate, washed with saturated NH4Cl solution,
saturated NaHCO3, 1 N HCl, water, brine, dried (Na2SO4), filtered,
and concentrated in vacuo. Chromatographic purification (SiO2, 50%
ethyl acetate in hexane eluant) of the residue provided compound 11
(S)-2,6-Diamino-N-((S)-6-amino-1-oxo-1-((4-((perfluoropyri-
din-4-yl)ethynyl)phenyl)amino)hexan-2-yl)hexanamide Tritri-
fluoroacetic Acid Salt (5). The Boc-deprotected compound 5 was
prepared by using the same procedure as synthesis of compound 3 in
1
(258 mg, 60%) as yellow solid. H NMR (400 MHz, CDCl3): δ 9.12
(bs, 1H), 7.65 (d, d, J = 8.6 Hz, 2H), 7.56 (d, J = 8.6 Hz, 2H), 6.51
(bs, 1H), 5.62 (bs, 1H), 5.31 (bs, 1H), 4.66 (bs, 1H), 4.25−4.13 (m,
1H), 4.09−3.99 (m, 1H), 3.52−2.97 (m, 4H), 1.98−1.89 (m, 1H),
1.87 −1.78 (m, 1H), 1.77 −1.62 (m, 4H), 1.61−1.30 (m, 33H). 13C
NMR (100 MHz, CDCl3): δ 172.8, 171.3, 156.3, 143.5 (dm, J = 245
Hz), 141.7 (dm, J = 264 Hz), 133.3, 119.6, 117.6, 115.5, 107.0, 80.6,
80.2, 79.2, 73.2, 55.1, 54.5, 49.2, 39.9, 33.9, 29.7, 28.8, 28.5, 28.4, 25.6,
24.9, 22.7, 22.6. MS (ESI): m/z (%) 845 (100) [M + Na]+. HRMS
(ESI): calcd for C40H54F4N6O8Na [M + Na]+ 845.38369, found
845.38406.
1
95% yield. H NMR (600 MHz, CD3OD): 7.71 (d, J = 8.7 Hz, 2H),
7.59 (d, J = 8.7 Hz, 2H), 4.51 (dd, J = 8.6, 5.2 Hz, 1H), 3.99 (t, J = 6.4
Hz, 1H), 2.92 (m, 4H), 1.98−1.42 (m, 12H). 13C NMR (100 MHz,
CD3OD): δ 172.6, 170.4, 163.4, 163.2, 144.9 (dm, J = 251 Hz), 143.3
(dm, J = 279 Hz), 142.1, 134.3, 121.2, 118.5, 117.1, 107.5, 74.0, 55.9,
54.1, 40.6, 40.4, 32.7, 32.1, 28.4, 28.1, 24.1, 22.6. MS (ESI): m/z (%)
523 (100) [M + H]+. HRMS (ESI): calcd for C25H31F4N6O2 [M +
H]+ 523.24446, found 523.24465.
t e r t - B u t y l N - [ ( 5 S ) - 5 - [ [ ( 2 S ) - 2 , 6 - B i s ( t e r t -
butoxycarbonylamino)hexanoyl]amino]-6-[3,4-bis[2-(2,3,5,6-
tetrafluoro-4-pyridyl)ethynyl]anilino]-6-oxo-hexyl]carbamate
(14). The peptide conjugate 14 was prepared by using the same
(S)-2,6-Diamino-N-((S)-5-amino-6-oxo-6-((4-((perfluoropyri-
din-4-yl)ethynyl)phenyl)amino)hexyl) hexanamide Tritri-
fluoroacetic Acid Salt (3). Boc-protected compound 11 (100 mg,
0.08 mmol) was dissolved in CH2Cl2 (2 mL) and cooled to 0 °C,
followed by addition of trifluoroacetic acid (2 mL). Reaction mixture
was stirred for 4 h and was poured in a centrifuge tube containing
anhydrous diethyl ether (15 mL). Immediately solid came out, and it
was centrifuged. The solid material was washed with anhydrous diethyl
ether (2 × 15 mL) to get pure TFA-salt 3 (95 mg, 90%) as white solid.
1H NMR (400 MHz, CD3OD): 7.78 (d, J = 8.6 Hz, 2H), 7.64 (d, J =
8.6 Hz, 2H), 4.04 (t, J = 6.6 Hz, 1H), 3.82 (t, J = 6.6 Hz, 1H), 3.29−
3.17 (m, 2H), 2.92 (t, J = 7.8 Hz, 2H), 2.06−1.76 (m, 4H), 1.73−1.57
(m, 4H), 1.56−1.39 (m, 4H). 13C NMR (100 MHz, CD3OD): δ
170.2, 169.1, 163.4, 163.0, 144.8 (dm, J = 245 Hz), 143.3 (dm, J = 264
Hz), 141.6, 134.3, 121.1, 117.4, 118.4, 107.3, 74.0, 55.2, 54.3, 40.3,
40.2, 32.3, 32.1, 29.9, 28.1, 23.3, 23.0. MS (ESI): m/z (%) 523 (100)
[M + H]+. HRMS (ESI): calcd for C25H31F4N6O2 [M + H]+
523.24446, found 523.24481.
1
procedure as synthesis of compound 11 in 62% yield. H NMR (400
MHz, CDCl3): δ 9.29 (bs, 1H), 8.16 (bs, 1H), 8.09−7.97 (m, 1H),
7.64 (d, J = 8.7 Hz, 1H), 6.59 (bs, 1H), 5.95 (bs, 1H), 4.84−4.50 (m,
3H), 4.08−4.01 (m, 1H), 3.23−3.03 (m, 4H), 1.96−1.31 (m, 39H).
MS (ESI): m/z (%) 1018 (100) [M + Na]+. HRMS (ESI TOF): calcd
for C47H53F8N7O8Na [M + Na]+ 1018.37256, found 1018.37108.
( S ) - 2 , 6 - D i a m i n o - N - ( ( S ) - 6 - a m i n o - 1 − 1 ( ( 3 , 4 - b i s -
((perfluoropyridin-4-yl)ethynyl)phenyl)amino)-1-oxohexan-2-
yl)hexanamide Tritrifluoroacetic Acid Salt (6). The Boc-depro-
tected compound 6 was prepared by using the same procedure as
synthesis of compound 3 in 86% yield. 1H NMR (400 MHz, CD3OD):
8.14 (d, J = 1.8 Hz, 1H), 7.79 (dd, J = 8.6, 1.8 Hz, 1H), 7.73 (d, J = 8.6
Hz, 1H), 4.54 (d, J = 8.7, 5.1 Hz, 1H), 3.99 (t, J = 6.3 Hz, 1H), 2.99−
2.91 (m, 4H), 2.03−1.79 (m, 4H), 1.79−1.60 (m, 4H), 1.66−1.45 (m,
4H). 13C NMR (150 MHz, CD3OD): δ 172.8, 169.1, 163.1, 145.7,
144.1, 142.6, 142.3, 135.2, 125.6, 124.4, 122.9, 119.8, 104.3, 103.8,
78.5, 78.2, 55.9, 54.1, 40.5, 40.4, 32.6, 32.4, 28.4, 28.2, 24.1, 22.8. MS
(ESI): m/z (%) 696 (100) [M + H]+. HRMS (ESI): calcd for
C32H30F8N7O2 [M + H]+ 696.23332, found 696.23180.
t e r t - B u t y l N - [ ( 1 S ) - 5 - [ [ ( 2 S ) - 2 , 6 - B i s ( t e r t -
butoxycarbonylamino)hexanoyl]amino]-1-[[3,4-bis[2-(2,3,5,6-
tetrafluoro-4-pyridyl)ethynyl]phenyl]carbamoyl]pentyl]-
carbamate (12). The peptide conjugate 12 was prepared by using
1
the same procedure as synthesis of compound 11 in 60% yield. H
Plasmid DNA Photocleavage. pBR322 plasmid DNA (4361 b/
p; from BioLabs Inc., 1 μg/μL solution in 10 mM Tris-HCl (pH 8.0),
and 1 mM EDTA buffer) was diluted to a concentration of 0.01 μg/
μL. The solution containing cleavage agent, DNA (38 μM/bp) in 20
mM sodium phosphate buffer was incubated for 1 h at 30 °C. Samples
were placed on ice at a distance of 20 cm from 200 W Hg−Xe lamp
(Spectra-Physics, Laser & Photonics Oriel Instruments with long pass
filter with 324 nm cut-on wavelength).
Electrophoretic Analysis. The gel electrophoresis was carried
out in 1× TBE buffer at 80 V using Miligel FisherBiotech horizontal
electrophoresis system. All gels were run on 1% agarose slab gels.
Before loading, the DNA samples were mixed with 0.33 volume of
tracking dye containing bromophenol blue (0.25%) and glycerol
(30%) in water. After staining in ethidium bromide solution (2 μg/
mL) for 1 h, the gel was washed with water and pictures were taken.
The relative quantities of the supercoiled and nicked, and linear DNA
were calculated by integrating the “area” of each spot by the image
analyzer software Total/Lab (Nonlinear Dynamics Ltd., UK). The
amount of supercoiled DNA was multiplied by a factor of 1.4 to
NMR (400 MHz, CDCl3): δ 9.54 (bs, 1H), 8.06 (d, J = 8.5 Hz, 1H),
7.73 (bs, 1H), 7.61 (d, J = 8.5 Hz, 1H), 6.69 (bs, 1H), 5.78−5.14 (bs,
2H), 4.69 (bs, 1H), 4.33−4.17 (m, 1H), 3.40−2.97 (m, 4H), 2.00−
1.19 (m, 39H). 13C NMR (100 MHz, CDCl3): δ 175.4, 174.3, 158.7,
158.2, 157.9, 146.2, 146.1, 143.7, 142.5, 135.2, 125.5, 124.5, 122.9,
119.5, 104.6, 103.9, 80.9, 80.7, 79.9, 57.0, 56.3, 41.1, 40.1, 33.2, 32.9,
30.6, 30.1, 28.9, 28.8, 27.1, 26.7, 24.3. MS (ESI): m/z (%) 1018 (100)
[M + Na]+. HRMS (ESI): calcd for C47H53F8N7O8Na [M + Na]+
1018.37256, found 1018.37340.
( S ) - 2 , 6 - D i a m i n o - N - ( ( S ) - 5 - a m i n o - 6 - ( ( 3 , 4 - b i s -
((perfluoropyridin-4-yl)ethynyl)phenyl)amino)-6-oxohexyl)-
hexanamide Tritrifluoroacetic Acid Salt (4). The Boc-depro-
tected compound 4 was prepared by using the same procedure as
synthesis of compound 3 in 85% yield. 1H NMR (600 MHz, CD3OD):
8.21 (s, 1H), 7.86−7.76 (m, 2H), 4.10−4.03 (m, 1H), 3.78−3.68 (m,
1H), 3.25−3.15 (m, 1H), 2.98−2.89 (m, 2H), 2.09−1.77 (m, 4H),
1.76−1.41 (m, 8H). 13C NMR (100 MHz, CD3OD): δ 170.2, 169.5,
163.5, 163.3, 162,.9, 159.4, 145.7, 144.2, 142.5, 141.8, 135.3, 125.7,
124.6, 123.1, 120.2, 117.7, 104.3, 103.8, 78.6, 78.3, 55.3, 54.4, 52.7,
8512
dx.doi.org/10.1021/jm2010282 | J. Med. Chem. 2011, 54, 8501−8516